hepatitis b virus carrier
Recently Published Documents


TOTAL DOCUMENTS

89
(FIVE YEARS 4)

H-INDEX

19
(FIVE YEARS 1)

2021 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Chorng-Kuang How ◽  
Li-Hua Li ◽  
Yu-Hui Chiu ◽  
Chen Meng ◽  
Wei-Fong Kao

2020 ◽  
Vol 286 ◽  
pp. 198085
Author(s):  
Shuling Jiang ◽  
Yun Zhu ◽  
Chen Cheng ◽  
Yue Li ◽  
Tai Ma ◽  
...  

2020 ◽  
Vol 158 (6) ◽  
pp. 1762-1775.e9 ◽  
Author(s):  
Thomas Michler ◽  
Anna D. Kosinska ◽  
Julia Festag ◽  
Till Bunse ◽  
Jinpeng Su ◽  
...  

2019 ◽  
Vol 58 (4) ◽  
pp. 569-574 ◽  
Author(s):  
Shoko Sonobe ◽  
Toru Arai ◽  
Yasushi Tanimoto ◽  
Chikatoshi Sugimoto ◽  
Masanori Kitaichi ◽  
...  

Hepatology ◽  
2017 ◽  
Vol 66 (4) ◽  
pp. 1067-1082 ◽  
Author(s):  
Yingjie Bian ◽  
Zheng Zhang ◽  
Zhichen Sun ◽  
Juanjuan Zhao ◽  
Danming Zhu ◽  
...  

2017 ◽  
Vol 27 (2) ◽  
pp. 185-186 ◽  
Author(s):  
Shigeto Yanagihara ◽  
Kazunari Sugita ◽  
Yuichi Yoshida ◽  
Daisuke Tsuruta ◽  
Osamu Yamamoto

2016 ◽  
Vol 10 ◽  
Author(s):  
Elena Garlatti Costa ◽  
Michela Ghersetti ◽  
Silvia Grazioli ◽  
Pietro Casarin

Acute hepatitis A is generally a self-limited disease in healthy subjects within few weeks, but an uncommon type of prolonged and biphasic acute course of hepatitis A infection has been also described. This type of presentation is observed in about 6-10% of patients, but a small number of reports, concerning this topic, are available in literature. In addition hepatitis A virus (HAV) infection in hepatitis B virus (HBV) carriers has rarely been discussed. A 41-year-old Italian man, already known to our Department for HBV infection as an inactive carrier HBsAg(+)ve, experienced a prolonged and biphasic course of acute hepatitis A, lasting about 7 months. In this patient possible factors, causing the second flare of transaminases, were excluded (in particular autoimmunity). Liver biopsy as well HAV RNA search in blood/stools were not performed. In conclusion, the hepatologist should take into account this type of atypical course in patients with HAV-related hepatitis and should promote HAV vaccination in subjects with HBV-chronic hepatitis, to prevent possible life-threatening acute exacerbation of hepatic damage, mainly in HBV-carriers with more severe forms of liver diseases.


Sign in / Sign up

Export Citation Format

Share Document